Literature DB >> 12354880

Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study.

A Espinel-Ingroff1, V Chaturvedi, A Fothergill, M G Rinaldi.   

Abstract

This collaborative three-center study evaluated NCCLS M38-A document testing conditions and other testing conditions for the antifungal susceptibility testing of 35 isolates of Aspergillus nidulans, A. terreus, Bipolaris hawaiiensis, B. spicifera, Cladophialophora bantiana, Dactylaria constricta, Fusarium solani, Paecilomyces lilacinus, Scedosporium prolificans, Trichoderma longibrachiatum, and Wangiella dermatitidis for itraconazole, three new triazoles (voriconazole, posaconazole, and ravuconazole), and amphotericin B. MICs and minimum fungicidal concentrations (MFCs) were determined in each center by using four media (standard RPMI-1640 [RPMI], RPMI with 2% dextrose [RPMI-2%], antibiotic medium 3 [M3], and M3 with 2% dextrose [M3-2%]) and two criteria of MIC determination (complete growth inhibition [MICs-0] and prominent growth inhibition [MICs-2]) at 24, 48 and 72 h. MFCs were defined as the lowest drug concentrations that yielded <3 colonies (approximately 99 to 99.5% killing activity). The reproducibility (within three wells) was higher among MICs-0 (93 to 99%) with either RPMI or M3 media than among all MICs-2 (86 to 95%) for the five agents at 48 to 72 h. The agreement for MFCs was lower (86 to 94%). Based on interlaboratory agreement, the optimal testing conditions were RPMI broth, 48 to 72 h of incubation and 100% growth inhibition (MIC-0); MFCs can be obtained after MIC determination with the above optimal testing parameters. These results warrant consideration for inclusion in the future version of the NCCLS M38 document. However, the role of these in vitro values as predictors of clinical outcome remains to be established in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12354880      PMCID: PMC130896          DOI: 10.1128/JCM.40.10.3776-3781.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

1.  Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.

Authors:  M H Nguyen; C J Clancy; V L Yu; Y C Yu; A J Morris; D R Snydman; D A Sutton; M G Rinaldi
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

Review 2.  Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature.

Authors:  P C Iwen; M E Rupp; A N Langnas; E C Reed; S H Hinrichs
Journal:  Clin Infect Dis       Date:  1998-05       Impact factor: 9.079

3.  In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.

Authors:  D A Sutton; S E Sanche; S G Revankar; A W Fothergill; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

4.  In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.

Authors:  E M Johnson; A Szekely; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1998-12       Impact factor: 5.790

5.  Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

6.  In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

Review 7.  Fatal disseminated Trichoderma longibrachiatum infection in an adult bone marrow transplant patient: species identification and review of the literature.

Authors:  S Richter; M G Cormican; M A Pfaller; C K Lee; R Gingrich; M G Rinaldi; D A Sutton
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

8.  In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species.

Authors:  C J Clancy; M H Nguyen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

9.  In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications.

Authors:  M R McGinnis; L Pasarell
Journal:  J Clin Microbiol       Date:  1998-08       Impact factor: 5.948

10.  Antifungal susceptibilities of Paecilomyces species.

Authors:  C Aguilar; I Pujol; J Sala; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

View more
  37 in total

1.  Internet-accessible DNA sequence database for identifying fusaria from human and animal infections.

Authors:  Kerry O'Donnell; Deanna A Sutton; Michael G Rinaldi; Brice A J Sarver; S Arunmozhi Balajee; Hans-Josef Schroers; Richard C Summerbell; Vincent A R G Robert; Pedro W Crous; Ning Zhang; Takayuki Aoki; Kyongyong Jung; Jongsun Park; Yong-Hwan Lee; Seogchan Kang; Bongsoo Park; David M Geiser
Journal:  J Clin Microbiol       Date:  2010-08-04       Impact factor: 5.948

2.  In vitro antifungal susceptibility of Sporothrix globosa isolates from Jilin Province, northeastern China: comparison of yeast and mycelial phases.

Authors:  Yang Song; Shanshan Li; Ying Shi; Lipei Zhao; Yu Cui; Lei Yao; Yu Zhen; Ruili Chen; Yan Cui
Journal:  Braz J Microbiol       Date:  2020-06-17       Impact factor: 2.476

3.  Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus successfully treated by oral voriconazole and nystatin packing.

Authors:  Ching-Yu Huang; Pei-Lun Sun; Hsiang-Kuang Tseng
Journal:  Mycopathologia       Date:  2011-03-20       Impact factor: 2.574

4.  Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.

Authors:  A Espinel-Ingroff; B Arthington-Skaggs; N Iqbal; D Ellis; M A Pfaller; S Messer; M Rinaldi; A Fothergill; D L Gibbs; A Wang
Journal:  J Clin Microbiol       Date:  2007-04-11       Impact factor: 5.948

5.  In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.

Authors:  Russell E Lewis; Nathan P Wiederhold; Michael E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

6.  Disulphide-reduced psoriasin is a human apoptosis-inducing broad-spectrum fungicide.

Authors:  Kyaw Zaw Hein; Hitoshi Takahashi; Toshiko Tsumori; Yukihiko Yasui; Yasuko Nanjoh; Tetsuo Toga; Zhihong Wu; Joachim Grötzinger; Sascha Jung; Jan Wehkamp; Bjoern O Schroeder; Jens M Schroeder; Eishin Morita
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-05       Impact factor: 11.205

7.  Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.

Authors:  Joseph Meletiadis; Charalampos Antachopoulos; Theodouli Stergiopoulou; Spyros Pournaras; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

8.  In vitro susceptibility of environmental isolates of Exophiala dermatitidis to five antifungal drugs.

Authors:  Ana Paula Miranda Duarte; Fernando Carlos Pagnocca; Noemi Carla Baron; Marcia de Souza Carvalho Melhem; Gislene Aparecida Palmeira; Dejanira de Franceschi de Angelis; Derlene Attili-Angelis
Journal:  Mycopathologia       Date:  2012-11-16       Impact factor: 2.574

9.  Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.

Authors:  Russell E Lewis; Ronen Ben-Ami; Leyla Best; Nathaniel Albert; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2012-12-13       Impact factor: 5.226

10.  Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.

Authors:  Cornelia Lass-Flörl; Astrid Mayr; Susanne Perkhofer; Guido Hinterberger; Johann Hausdorfer; Cornelia Speth; Manfred Fille
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.